OpenAI and Moderna announce partnership to improve vaccines and treatments

The companies OpenAI e Modern signed a partnership involving the Chat GPT Enterprise, the main product of OpenAI for corporations. A Modern, a biotechnology company, is known especially for its vaccine against COVID-19, which uses messenger RNA technology. With the partnership, the Modern aims to empower its employees with artificial intelligence, creating new opportunities and accelerating the impact of each team. Since the beginning of 2023, Moderna has collaborated with OpenAI, and now, with the agreement involving the Chat GPT Enterprise, the company is transforming the way it operates in all areas.

With more than a decade of experience in science, technology and health, Modern is set to launch up to 15 new products over the next five years, including a Respiratory Syncytial Virus (RSV) vaccine and personalized cancer treatments. All this with the Chat GPT Enterprise involved in new drug development functions.

How partnership can improve vaccine development

A Modern adopted generative artificial intelligence (AI) with the same strategic approach used for other technologies: seeking to maximize its positive impact on patients through digital. To ensure AI was integrated effectively, the company focused on starting with the user, investing in creating a solid foundation for this paradigm shift. The ambitious goal of Modern was to achieve 100% adoption and proficiency in generative AI by all employees with access to digital solutions.

To achieve this challenging goal, the Modern assembled a team of dedicated experts to lead a customized transformation program. The company's approach combined individual, collective and structural change management initiatives. Individual initiatives included in-depth research, listening programs, and in-person and online training, as well as partnerships with colleagues dedicated to learning about AI.

All this work set the stage for success with the launch in early 2023 of an internal AI chatbot called mChat, built on the API OpenAI. O mChat was adopted by more than 80% of employees, establishing a solid foundation so that, now, Modern adopt the ChatGPT Enterprise.

We deeply believe at Moderna that ChatGPT and OpenAI will change the world. We're looking at every business process — from legal to research to manufacturing to commercial — and thinking about how to redesign them with AI

Stéphane Bancel, CEO of Moderna

With the launch of ChatGPT Enterprise, a Modern faced the decision of whether to continue development of mChat as an all-in-one AI tool or to make C availablehatGPT Enterprise for your employees. Brice Challamel, head of AI products and platforms at Modern, explained that the company conducted extensive comparative tests between the mChat, Copilot and the Chat GPT Enterprise. After analysis, the team discovered that the Chat GPT Enterprise it was the solution preferred by users, with an exceptionally high net promoter score. Based on these results, the Modern decided to bet on ChatGPT Enterprise as its main AI tool.

After implementing the Chat GPT Enterprise, employees of Modern gained the ability to easily create their own GPTs, the results exceeded expectations in the first few months after adopting ChatGPT Enterprise. The company had 750 GPTs across the organization, 40% of weekly active users were creating GPTs, and each user was having an average of 120 conversations with the Chat GPT Enterprise per week. These numbers demonstrate the significant impact that the implementation of AI has had on the company, driving innovation and efficiency in all areas.

With Chat GPT Enterprise, Modern is developing and validating solutions such as Dose ID, a GPT pilot designed to review and analyze clinical data. This data analysis assistant aims to increase the clinical judgment and decision-making of the clinical trial team by efficiently integrating and visualizing large data sets.

Dose ID is already demonstrating its potential. Meklit Workneh, Director of Clinical Development at Modern, highlighted that the tool provided justifications for specific dose choices, created personalized visualizations and facilitated multidimensional data analysis. This approach, combining human analysis with AI, is prioritizing safety and optimizing the vaccine profile ahead of final clinical trials.

Furthermore, Modern is transforming its operations in several areas with the Chat GPT Enterprise. The legal team, for example, achieved 100% technology adoption, allowing them to focus on critical patient issues. The company also implemented Contract Companion GPT and Policy Bot GPT to improve compliance and simplify internal policies, demonstrating the broad reach and versatility of AI within the organization.

With an ambitious plan to launch several products in the coming years, the Modern sees AI as a fundamental piece to its success and to maintaining efficiency as a company. Stéphane Bancel, CEO of Modern, emphasized the importance of maximizing the impact on patients with a lean team, using technology and AI to grow the company sustainably.

If we had to do this the old, biopharma way, we might need a hundred thousand people today (…) We really believe we can maximize our impact on patients with a few thousand people, using technology and AI to grow the company.

Stéphane Bancel, CEO of Moderna

OpenAI bets on ChatGPT Enterprise

A OpenAI launched the Chat GPT Enterprise in 2023, offering advanced features for enterprise customers such as enhanced security, customization options, and advanced data analysis capabilities. O.C.hatGPT Enterprise offers unlimited high-speed access to GPT-4, with all interactions protected by encryption during transmission and storage. The tool operates up to twice as fast as standard GPT-4 and includes a 32-token context window, allowing it to process inputs and files four times larger.

One of the main characteristics of Chat GPT Enterprise is unlimited access to Advanced Data Analytics, formerly known as Code Interpreter. This role allows technical and non-technical teams to analyze information quickly, meeting diverse needs, from market analysis to script debugging.

According to OpenAI, still in 2023, the Chat GPT Enterprise had already been adopted by more than 80% of Fortune 500 companies, including companies such as Canva e PwC. At the beginning of April this year, the executive president of OpenAI, Sam Altman, received hundreds of executives from companies in San Francisco, New York and London to present artificial intelligence services for corporate use.

See also:

See also: OpenAI, Modern e YouTube OpenAI

reviewed by Glaucon Vital in 25 / 4 / 24.